305 related articles for article (PubMed ID: 18625722)
21. Stability of Smyd1 in endothelial cells is controlled by PML-dependent SUMOylation upon cytokine stimulation.
Becker S; Steinemann G; Karle W; Roos K; Liem CH; Muralikumar S; Volkamer A; Munz B; Zakrzewicz A; Berkholz J
Biochem J; 2021 Jan; 478(1):217-234. PubMed ID: 33241844
[TBL] [Abstract][Full Text] [Related]
22. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
23. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
24. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
25. Identification of RNF168 as a PML nuclear body regulator.
Shire K; Wong AI; Tatham MH; Anderson OF; Ripsman D; Gulstene S; Moffat J; Hay RT; Frappier L
J Cell Sci; 2016 Feb; 129(3):580-91. PubMed ID: 26675234
[TBL] [Abstract][Full Text] [Related]
26. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
27. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
28. Unravelling the molecular interplay: SUMOylation, PML nuclear bodies and vascular cell activity in health and disease.
Berkholz J; Karle W
Cell Signal; 2024 Jul; 119():111156. PubMed ID: 38574938
[TBL] [Abstract][Full Text] [Related]
29. Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.
Ho CL; Huang YC; Tai CK; Liu ST; Wang JK; Wang WM; Huang SM
Int J Biochem Cell Biol; 2010 Jun; 42(6):902-10. PubMed ID: 20097304
[TBL] [Abstract][Full Text] [Related]
30. SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.
Han Y; Huang C; Sun X; Xiang B; Wang M; Yeh ET; Chen Y; Li H; Shi G; Cang H; Sun Y; Wang J; Wang W; Gao F; Yi J
J Biol Chem; 2010 Apr; 285(17):12906-15. PubMed ID: 20181954
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Sp1 functions by its sequestration into PML nuclear bodies.
Li J; Zou WX; Chang KS
PLoS One; 2014; 9(4):e94450. PubMed ID: 24728382
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
33. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies.
Reineke EL; Kao HY
Int J Biol Sci; 2009 May; 5(4):366-76. PubMed ID: 19471587
[TBL] [Abstract][Full Text] [Related]
34. Two-step colocalization of MORC3 with PML nuclear bodies.
Mimura Y; Takahashi K; Kawata K; Akazawa T; Inoue N
J Cell Sci; 2010 Jun; 123(Pt 12):2014-24. PubMed ID: 20501696
[TBL] [Abstract][Full Text] [Related]
35. CACUL1/CAC1 attenuates p53 activity through PML post-translational modification.
Fukuda T; Kigoshi-Tansho Y; Naganuma T; Kazaana A; Okajima T; Tsuruta F; Chiba T
Biochem Biophys Res Commun; 2017 Jan; 482(4):863-869. PubMed ID: 27889610
[TBL] [Abstract][Full Text] [Related]
36. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
[TBL] [Abstract][Full Text] [Related]
37. Patient mutations alter ATRX targeting to PML nuclear bodies.
Bérubé NG; Healy J; Medina CF; Wu S; Hodgson T; Jagla M; Picketts DJ
Eur J Hum Genet; 2008 Feb; 16(2):192-201. PubMed ID: 17957225
[TBL] [Abstract][Full Text] [Related]
38. Viral disruption of promyelocytic leukemia (PML) nuclear bodies by hijacking host PML regulators.
Frappier L
Virulence; 2011; 2(1):58-62. PubMed ID: 21217204
[TBL] [Abstract][Full Text] [Related]
39. Arkadia, a novel SUMO-targeted ubiquitin ligase involved in PML degradation.
Erker Y; Neyret-Kahn H; Seeler JS; Dejean A; Atfi A; Levy L
Mol Cell Biol; 2013 Jun; 33(11):2163-77. PubMed ID: 23530056
[TBL] [Abstract][Full Text] [Related]
40. Functional reorganization of promyelocytic leukemia nuclear bodies during BK virus infection.
Jiang M; Entezami P; Gamez M; Stamminger T; Imperiale MJ
mBio; 2011; 2(1):e00281-10. PubMed ID: 21304169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
